Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-02 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권) (2025.05)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement) filed by Cellid Co., Ltd. in South Korea. It details specific amendments to the 'Investment Risk Factors' and 'Use of Proceeds' sections of a previously filed securities registration statement. This is a formal regulatory filing required for public offerings of equity securities, which falls under the category of Regulatory Filings (RNS) as it is a specific regulatory document that does not fit into the other specialized categories like 10-K or Earnings Release.
2025-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, auditor reports, and director/auditor appointments. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-03-26 Korean
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official filing titled '정기주주총회결과' (Results of the Annual General Meeting) for the company Cellid. It details the outcomes of shareholder votes on agenda items such as financial statement approval, director/auditor appointments, and remuneration limits. This falls directly under the definition of a Declaration of Voting Results (DVA).
2025-03-26 Korean
증권신고서(지분증권) (2025.05)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed by Cellid Co., Ltd. with the Financial Services Commission of South Korea. It details a capital raise (8,400,000 shares) and includes extensive sections on investment risks, business operations, and financial status. This document is a formal regulatory filing for a public offering of securities, which falls under the 'Regulatory Filings' category as it is a primary registration document for capital issuance.
2025-03-19 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the issuance of new shares, pricing methods, subscription dates, and underwriting arrangements. This falls under the category of capital structure changes and financing activities.
2025-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Cellid. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor (Samjong Accounting Corp). While it contains financial data, it is a specific regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a standalone audit report document. In the context of Korean regulatory filings (DART/KIND), this is a standard disclosure of the audit report's submission and its key findings. FY 2024
2025-03-18 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.